welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology
Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
expertly curated content related to this topic
-
James Church, MDJames M. Church, MD, is a staff member i...
-
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
-
Rectum-sparing Surgery may be Appropriate for Biallelic MutYH-Associated PolyposisPURPOSE: The risk of cancer or severe p...
-
Rofecoxib Reduces Polyp Recurrence in Familial Polyposis.The long-term (mean of 16.4 +/- 4.2 mont...
-
Leids Universitair Medisch CentrumThe center conducts research in the fiel...
-
Rectal Epithelial Apoptosis in Familial Adenomatous Polyposis Patients Treated with SulindacBACKGROUND : Sulindac regresses colorect...
-
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal SurgeryThis will be a prospective, multi-center...